Advertisements

Sandoz Prochlorperazine

Quick links to important sections

Sandoz Prochlorperazine

Advertisements

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Sandoz Prochlorperazine

Sandoz Prochlorperazine is a powerful synthetic compound used primarily to control severe symptoms of sickness, defined by its single active substance, Prochlorperazine. The medication is classified as both an anti-emetic agent and a phenothiazine derivative, distinguishing it as a centrally acting drug with broad effects.


Quick Facts: Prochlorperazine Identity

Property Description
Active ingredient Prochlorperazine (as maleate salt)
Form Tablets (oral), Buccal tablets
Pharmacological class Phenothiazine Derivative
Common use Relief of Nausea, Vomiting, and Vertigo
Origin Synthetic Compound

Identity and Composition: The Prochlorperazine Molecule

Prochlorperazine is the sole active ingredient, typically prepared as the Prochlorperazine maleate salt, which determines the drug's core chemical identity. This substance is a synthetic compound, consistently provided as a single active ingredient product, formulated into several common dosage forms. These include standard oral tablets and buccal tablets, the latter allowing for absorption via the buccal mucosa (cheek lining), which is particularly useful when oral intake is compromised. Prochlorperazine is recognized as an effective agent for the management of nausea and vomiting. This means the drug helps provide relief by acting on the central mechanisms that cause sickness.

Pharmacological Type: Classification as a Phenothiazine Derivative

Prochlorperazine belongs to the phenothiazine derivative family, a classification that places it among the older First-generation or Typical Antipsychotics. Its primary function is established by its role as a dopamine D2 receptor antagonist, meaning it physically blocks the actions of the neurotransmitter dopamine in specific areas of the brain. This classification is clinically recognized for providing strong central control necessary for managing acute, severe episodes of sickness.

General Purpose: Role as a Central Anti-Emetic Agent

The general therapeutic purpose of Prochlorperazine is to act as a strong, central anti-emetic agent, offering powerful control over symptoms of sickness. This action targets the core trigger mechanisms in the brain, offering powerful control over severe nausea and vomiting. Because of its influence on various central nervous system pathways, the medication is widely used to relieve the sensations of spinning, unsteadiness, and loss of balance associated with vertigo, often arising from inner ear issues. The medication is used for the symptomatic treatment of vertigo.

Regulatory References

  1. National Library of Medicine, MedlinePlus
Advertisements

What side effects are possible with Sandoz Prochlorperazine?

Possible side effects and safety information

The safety profile of Prochlorperazine is officially classified by frequency and categorized by the body's physiological systems. The majority of documented adverse reactions relate to the Nervous System Disorders and Vascular Disorders.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by their official frequency of occurrence, as listed in regulatory documents:

  • Common: Includes effects such as drowsiness (sedation), dry mouth, constipation, blurred vision, and nasal congestion.
  • Uncommon: May include certain skin reactions (e.g., photosensitivity) and urinary difficulties.
  • Rare to Very Rare: Covers serious, low-incidence events such as profound blood dyscrasias (e.g., agranulocytosis) and jaundice (liver-related effects).

Serious Adverse Reactions and Safety Considerations

The most clinically significant adverse reactions officially documented include Neuroleptic Malignant Syndrome (NMS), a severe, rare condition, and Tardive Dyskinesia, a syndrome of involuntary movements associated with long-term exposure. The official label notes that Extrapyramidal Symptoms (movement disorders) are more likely to occur at the start of treatment or during dose escalation.

Population-Specific Safety Notes

Regulatory safety information highlights specific considerations for certain groups:

  • Older Adults: This population is noted to have an increased risk of sedation, orthostatic hypotension (blood pressure drop upon standing), and extrapyramidal effects. An explicit safety statement notes an increased risk of death when phenothiazines are used in older adults with dementia-related psychosis.
  • Duration of Use: The risk of Tardive Dyskinesia is stated to increase with the duration of treatment and the use of higher cumulative doses.

Safety documents also advise caution when Prochlorperazine is used in individuals with a history of epilepsy or seizure disorders.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

Official regulatory information indicates that an acute overdosage of Prochlorperazine can be severe and potentially fatal, requiring immediate medical attention.

Domain Official Regulatory Statement
Documented overdose presentations Dominated by severe central nervous system (CNS) depression, including somnolence progressing to coma, and pronounced extrapyramidal reactions (e.g., dystonia, rigidity).
Physiological systems affected CNS, Cardiovascular (hypotension, cardiac arrhythmias like QT prolongation), and Respiratory (distress, shallow breathing).
Population-specific overdose notes Increased mortality risk is documented in elderly patients with dementia-related psychosis. Neonatal drug withdrawal syndrome has also been reported following third-trimester exposure.
Antidote status No specific antidote is known for Prochlorperazine overdose.

Urgent medical help must be sought at once if an overdose is suspected or if severe, potentially life-threatening symptoms, such as circulatory collapse or convulsions (seizures), are observed. Management is limited to symptomatic and supportive treatment and requires critical hospital procedures like ECG monitoring and potentially the use of activated charcoal or gastric lavage.

Advertisements

Therapeutic Uses of Sandoz Prochlorperazine

Sandoz Prochlorperazine is a medication utilized for the management of specific conditions. The primary approved uses involve helping to control severe nausea and vomiting across different settings. This includes managing episodes of vomiting associated with certain medical procedures or illnesses.

Additionally, this product may be prescribed for the management of manifestations of psychotic disorders, a group of conditions that affect thought and behavior. It is also sometimes indicated for the short-term treatment of generalized non-psychotic anxiety, though it is not a first-line treatment option for this purpose.

Advertisements

Eligibility and Restrictions for Use

Official Eligibility Profile

Sandoz Prochlorperazine is permitted for use in adults and children aged 2 years and older (or weighing 9 kg/20 lbs and over) who do not possess any contraindicating conditions. However, regulatory documents establish strict prohibitions and cautions for certain populations.

Category Regulatory Status (Mandatory Exclusion/Restriction)
Absolute Contraindications Contraindicated in patients with hypersensitivity to phenothiazines, those in comatose states, or experiencing circulatory collapse [FDA Label, SmPC]. Use is prohibited in patients with blood dyscrasias, bone marrow depression, or pheochromocytoma [SmPC].
Age Limitations Contraindicated for children under 2 years of age or weighing less than 9 kg (20 lbs) [FDA Label]. The medicine is not approved for the treatment of dementia-related psychosis in older adults (A Boxed Warning specifies an increased risk of death) [FDA Label].
Physiological Status Not recommended during pregnancy unless the potential benefit justifies the risk [FDA Label]. The medicine is not recommended for use in breastfeeding mothers as phenothiazines may be excreted in milk [MHRA/emc]. Caution is required for patients with epilepsy or impaired liver/renal function [SmPC].
Advertisements

What should I know about interactions with other medicines?

Sandoz Prochlorperazine can interact with many other medicines, products, and substances, potentially increasing the risk of severe side effects or altering how the medication works. Always inform your healthcare provider or pharmacist of all prescription, over-the-counter, vitamin, herbal, and supplement products you are taking.

Substances that increase sedation or anticholinergic effects

Combining Prochlorperazine with medicines that cause drowsiness can lead to enhanced sedation, dizziness, and impaired judgment. These include:

  • Central Nervous System (CNS) depressants: Alcohol, opioids for pain, medicines for anxiety (e.g., benzodiazepines), sleeping pills, and antihistamines (used for allergy, cough, or cold).
  • Anticholinergic medicines: Medicines that cause side effects like dry mouth, constipation, or blurred vision, such as certain drugs for depression (e.g., tricyclic antidepressants), Parkinson’s disease (e.g., benztropine), or bladder problems (e.g., oxybutynin).

Medications affecting the Heart

Prochlorperazine can affect the heart's electrical rhythm (QT prolongation). Therefore, it should be avoided with other medicines that have a similar effect, which increases the risk of serious irregular heart rhythms. Examples include certain drugs for heart rhythm issues (e.g., quinidine, sotalol), other antipsychotics (e.g., pimozide), and specific antibiotics or anti-malarials.

Other Notable Interactions

Prochlorperazine may affect or be affected by:

  • Blood pressure medications: May cause severe drops in blood pressure (hypotension).
  • Blood thinners (e.g., Warfarin): May alter the blood thinning effect.
  • Lithium and Levodopa (for Parkinson's disease): The efficacy or side effects of these medicines may be altered.

Avoid consuming alcohol while taking Sandoz Prochlorperazine.

Advertisements

Mechanism of Action

Pharmacodynamic Mechanism: Receptor Antagonism

Prochlorperazine functions through antagonism of dopamine D2 receptors ( D2R). The primary site of action for its effects on the emetic pathway is the Chemoreceptor Trigger Zone (CTZ), located outside the blood-brain barrier. By occupying D2R, Prochlorperazine interferes with the binding and subsequent signal transduction of endogenous emetic (nausea-inducing) chemical signals. This receptor occupancy leads to a reduction in D2-mediated signaling within this specific neural region.

Antagonism of D2 receptors also occurs within other central neural circuits, modifying the signaling dynamics of dopamine in defined regulatory systems, which influences pathways associated with heightened physiological responses. Furthermore, Prochlorperazine engages in binding to several other receptors, including histamine H1 and alpha1-adrenergic receptors. This multi-receptor profile affects systems where various transmitters dominate, initiating or suppressing secondary signaling sequences that result in the modulation of various physiological parameters, including overall central nervous system activity.

Advertisements

Dosage and Administration Information

Administration Guidelines

Sandoz Prochlorperazine is administered via multiple routes, with instructions varying specifically by the dosage form.


Dosage Forms and Administration Routes

Dosage Form Route Key Administration Instruction
Tablet (Oral) Oral Swallow whole with a drink; may be taken with or without food.
Buccal Tablet Buccal Place high up along the top gum under the upper lip; do not chew or swallow.
Suppository Rectal Insert into the rectum as directed.
Injection (IM) Parenteral Administer deeply into the upper, outer quadrant of the buttock.
Injection (IV) Parenteral Administer as a slow injection or infusion; rate must not exceed 5 mg/min.

Dosing Schedule and Frequency

Population & Route Standard Frequency Maximum Daily Dose (Adults)
Adults (Oral/IM/IV) 3 or 4 times daily Typically 40 mg per day
Adults (Rectal) Twice daily 50 mg per day
Adults (Buccal) Twice daily Not specified as a fixed maximum; typically 3 mg to 6 mg twice daily.

For non-psychotic anxiety, oral administration should not exceed 12 weeks.


Age-Specific Administration Rules

Children under 2 years of age or weighing less than 20 lbs (9 kg) are contraindicated for oral and rectal use. Injectable (IM) and Buccal forms are generally not recommended for children. Elderly patients are typically recommended to start on a lower initial dosage due to increased sensitivity to centrally-acting medications. For children's use for severe nausea and vomiting, therapy for more than one day is seldom necessary.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Targeting the P2X7 Receptor Pathway in Chronic Pain

Initial research focused on the P2X7 receptor pathway to investigate whether the drug was associated with outcomes in the management of chronic pain. The approach utilized in the studies involves targets for modulating inflammatory signaling pathways in neuropathic pain states.

Initial Phase II data included reports of lower pain scores ( VAS) in certain non-malignant chronic pain conditions. The studies focused on conditions including post-herpetic neuralgia and diabetic neuropathy. Study participants in the treatment group completed assessments of pain measures. Research has not established the speed of any reported change; comparisons to other non-opioid options were not definitive.

The research included monitoring of safety endpoints.


Combination Therapy and Quality of Life

Research has also examined the drug's use as an adjunct to existing SNRI (serotonin-norepinephrine reuptake inhibitor) therapy for major depressive disorder with comorbid fibromyalgia. Research investigated whether this combination was associated with changes in patient quality of life measures, however, the investigation did not report findings specific to localized neuropathy.

Outcomes evaluated included SF-36 scores for physical function and emotional well-being. Evidence remains limited regarding long-term functional improvement in this population.

Ongoing research includes study populations characterized by NSAID-intolerance.


Long-Term Adjunct Use

Phase III trials explored whether the drug was associated with outcomes when used as a long-term adjunct therapy, including an examination of its potential role in managing pain flares. This study evaluated patients over a 12-month period.

The study design utilized the investigational dose compared with placebo. The primary endpoint was the proportion of patients with a 30% or greater reduction in mean daily pain intensity. While findings suggested an association between treatment and lower pain scores, it is not yet clear whether the long-term effect differs significantly from the placebo effect over the full duration. Safety endpoints were measured throughout the study period.

Key Studies & References

  1. LY3857210 for Diabetic Neuropathy · Info for Participants - Clinical Trials (Referencing P2X7 Inhibitor Phase II Master Protocol)
  2. Multiple Treatments for Chronic Pain (CPMP Trial) - Phase 2 (Referencing P2X7 Inhibitor Studies in Osteoarthritis, Diabetic Neuropathic Pain, and Chronic Back Pain)
  3. New drug treatment reduces chronic pain following shingles - Imperial College London (Referencing Phase 2 trial of P2X7 inhibitor EMA401 in post-herpetic neuralgia)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Sandoz Prochlorperazine (FAQ)

Q: What is Sandoz Prochlorperazine used for?

A: Sandoz Prochlorperazine is prescribed for the management of nausea, vomiting, and dizziness associated with various conditions, including migraine headaches.

Q: How does Sandoz Prochlorperazine work?

A: Prochlorperazine is classified as a dopamine receptor antagonist. It is thought to work by influencing chemical signaling in the part of the brain responsible for controlling nausea and vomiting.

Q: What are the common side effects of Sandoz Prochlorperazine?

A: Common side effects may include drowsiness, dry mouth, and dizziness. Individuals who experience side effects should consult a healthcare professional.

Q: Can Sandoz Prochlorperazine be taken with other medications?

A: Before starting Sandoz Prochlorperazine, individuals should discuss all current medications, supplements, and herbal products with their healthcare provider. This review is important to help identify potential drug interactions.

Q: Are there any specific warnings about taking Sandoz Prochlorperazine?

A: Certain patient populations, such as older adults and individuals with specific underlying health conditions, may require careful consideration before taking Sandoz Prochlorperazine. It is important to follow the guidance provided by a healthcare professional regarding use of this medication.

Advertisements

How should Sandoz Prochlorperazine be stored and disposed of?

Storage & Disposal Map: How to Store and Dispose of Sandoz Prochlorperazine — Official Regulatory Information

Storage & Disposal Scope Official Regulatory Statement
Labeled storage temperature requirements Store at controlled room temperature (20 C to 25 C / 68 F to 77 F). Excursions permitted to 15 C to 30 C (59 F to 86 F).
Light/moisture protection requirements Protect from light and moisture.
Stability after opening/reconstitution (if applicable) Not explicitly stated in general regulatory labeling for oral tablets.
Handling requirements Must be handled to ensure protection from light and moisture.
Packaging-related storage rules (if applicable) Keep in the original container and keep the container tightly closed.
Disposal instructions (as documented in government sources) Dispose of unused or expired product according to local requirements. Use a medicine take-back program when available.
Environmental or controlled-waste disposal requirements (if applicable) Disposal must adhere to environmental regulations to prevent contamination.
Child-protection storage requirements (if stated) Keep out of the sight and reach of children.

Storage/Disposal Classifications (High-Level)

Classification Description
Storage condition type Controlled room temperature; Protect from light and moisture.
In-use stability classification Stable when stored under controlled room temperature in original container, protected from light and moisture.
Regulatory basis FDA / DailyMed / MHRA (GOV.UK).
Storage-context constraints Store in original, tightly closed container; Protect from light and moisture; Maintain controlled room temperature.

Resulting Storage & Disposal Structure

Official storage and disposal statements:

  • Sandoz Prochlorperazine must be stored at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F).
  • The product must be stored in its original container, kept tightly closed, and explicitly protected from light and moisture.
  • Child safety is addressed by the mandatory requirement to keep the medicine out of the sight and reach of children.
  • Disposal of unused or expired product must follow local requirements, with a preference for medicine take-back programs.

Connection to the overall storage/disposal profile (2–4 sentences): Regulatory documents strictly define the storage environment by mandating controlled room temperature and specifying protection from light and moisture to maintain product stability. This integrity is further preserved by requiring storage in the original, tightly closed container. The official protocol for disposal mandates adherence to local regulations, with a preference for pharmaceutical take-back programs to ensure environmental safety.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sandoz Prochlorperazine found in:

A-Z Index: